Clinical NewsMRILanyardsMay 8, 2022Latest in MRIISMRM: Insulin resistance in women associated with less myelin, changes in brainMay 10, 2025SponsoredEchelon Synergy 1.5T MRI with MotionClear Comprehensive Motion Correction SuiteJanuary 1, 2025ISMRM: Trimodal PET-MR-FUS may be feasible therapy monitoring optionMay 10, 2025ISMRM: Switching between full and short breast MRI reduces recallsMay 10, 2025Related StoriesMRIHow exactly does AI promise to transform clinical practice in MRI?MRIPersonal approach enables MRI in autistic patientsMRIEconomic factors limit clinical adoption of 7T MRI systemsSponsor ContentEchelon Synergy 1.5T MRI with MotionClear Comprehensive Motion Correction Suite
.fFmgij6Hin.png?auto=compress%2Cformat&fit=crop&h=100&q=70&w=100)
.fFmgij6Hin.png?auto=compress%2Cformat&fit=crop&h=167&q=70&w=250)
![Images depict axial MRI scans in a 50-year-old premenopausal female patient with biopsy-proven 12-mm invasive lobular cancer in the lower outer quadrant of the left breast. Upper images are subtracted dynamic contrast-enhanced (DCE) MRI scans from the first and second postcontrast acquisitions. Lower images are ultrafast MRI scans obtained within 24 hours after the DCE study (four consecutive subtracted dynamic frames from time points [T] 6–9). There is marked background parenchymal enhancement (BPE) on the DCE MRI scans. Thus, the known cancer (arrow) is barely visible; it exhibits only slightly stronger enhancement than the normal fibroglandular tissue, which results in low conspicuity. At ultrafast MRI there is less BPE, and still the cancer is barely visible because it starts to enhance simultaneously with the BPE. The conspicuity of the cancer is even reduced compared with the DCE series. Both of the readers missed this cancer on both the DCE and ultrafast MRI scans.](https://img.auntminnie.com/mindful/smg/workspaces/default/uploads/2025/05/2025-05-06-rsna-ultrafast-dce-mri-breast.Gzvq76udFr.jpg?auto=format%2Ccompress&dpr=2&fit=crop&h=167&q=70&w=250)
